BioAlberic: an alternative for hypercholesterolemia?

Abstract

Introduction: Despite the progress made in the diagnosis and treatment of dyslipidemias, therapeutic goals are often not reached due to noncompliance of medical indications by some patients or to the presence of adverse reactions to lipid lowering drugs. The use of the BioAlberic method can be another therapeutic alternative.

Objective: To assess the effectiveness of the method in the treatment of hypercholesterolemia.

Method: A controlled, randomized, open-label pilot study was designed. The sample was composed of 60 patients with hypercholesterolemia. Patients were divided into three groups of 20 each: group I treated with coltricé 1, Group II treated with coltricé 2 and group III to whom 20 mg of atorvastatin were administered. Treatment consisted of the oral administration of the BioAlberic product, used in drinking water over a period of 90 days, with a monthly monitoring. At the beginning of the research the serum levels of cholesterol, triglycerides, glutamic pyruvic transaminase and oxaloacetic, uric acid, creatinine, and glucose were determined. Total plasma cholesterol and triglycerides were assessed monthly for three months, and levels at the beginning and end of the research were compared.

Results: Cholesterol was normalized in 12 patients with the use of coltricé (between 9.6 and 6.02 mmol/L), 11 reached borderline levels (from 10.43 to 5.9 mmol/L) and there was no response in 17.

Conclusions: Administration of coltricé could be another therapeutic option in the treatment of hypercholesterolemia.